Premature Labor (Tocolysis) - Pipeline Review, H2 2017

Published: Aug, 2017 | Pages: 50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Premature Labor (Tocolysis) - Pipeline Review, H2 2017, provides an overview of the Premature Labor (Tocolysis) (Women's Health) pipeline landscape.

Preterm labor or premature labor is defined as labor that begins before completion of 36 weeks of pregnancy. Symptoms include sensation of pelvic or lower abdominal pressure, mild abdominal cramps, diarrhea, vaginal spotting or bleeding and constant low, dull backache. Treatment includes corticosteroids and tocolytics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Premature Labor (Tocolysis) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Premature Labor (Tocolysis) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Premature Labor (Tocolysis) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis) (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Premature Labor (Tocolysis) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Premature Labor (Tocolysis) (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Premature Labor (Tocolysis) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Premature Labor (Tocolysis) (Women's Health)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Premature Labor (Tocolysis) (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Premature Labor (Tocolysis) - Overview
Premature Labor (Tocolysis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Premature Labor (Tocolysis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development
AMAG Pharmaceuticals Inc
GlaxoSmithKline Plc
Juniper Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Lipocine Inc
ObsEva SA
Premature Labor (Tocolysis) - Drug Profiles
bedoradrine sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydroxyprogesterone caproate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydroxyprogesterone caproate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OBE-022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
progesterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
retosiban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Acute Inflammation and Premature Labor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Premature Labor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Premature Labor (Tocolysis) - Dormant Projects
Premature Labor (Tocolysis) - Discontinued Products
Premature Labor (Tocolysis) - Product Development Milestones
Featured News & Press Releases
Jun 29, 2017: ObsEva Announces To Present on OBE022 at ESHRE 2017 Annual Meeting
Jun 26, 2017: AMAG Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Makena (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector
Jun 26, 2017: Lipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
May 18, 2017: ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022
Apr 17, 2017: AMAG Submits Supplemental New Drug Application to FDA for Makena (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use
Mar 17, 2017: ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor
Feb 02, 2017: AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration
Jan 13, 2017: ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor
Jan 09, 2017: Lipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
Oct 12, 2016: AMAG Pharmaceuticals Announces Achievement of Key Milestone in Next Generation Development Program for Makena
Jul 28, 2016: ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2a Antagonist, for the Treatment of Preterm Labor
Apr 04, 2016: AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)
Feb 23, 2016: AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)
Feb 16, 2016: Lipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women
Jan 11, 2016: Juniper Pharmaceuticals provides Update on JNP-0301
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Premature Labor (Tocolysis), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Premature Labor (Tocolysis) - Pipeline by AMAG Pharmaceuticals Inc, H2 2017
Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline Plc, H2 2017
Premature Labor (Tocolysis) - Pipeline by Juniper Pharmaceuticals Inc, H2 2017
Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017
Premature Labor (Tocolysis) - Pipeline by Lipocine Inc, H2 2017
Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H2 2017
Premature Labor (Tocolysis) - Dormant Projects, H2 2017
Premature Labor (Tocolysis) - Discontinued Products, H2 2017